AbbVie ends 11-year Calico partnership focused on aging research
FierceBiotech - 12-Nov-2025AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
Join the club for FREE to access the whole archive and other member benefits.
AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
Scientists uncover new bacterial genomes and two potent antibiotic leads from soil
Using donated organs, Revalia aims to cut drug failures and speed safe treatments to patients
Orforglipron offers a needle-free option for tackling obesity, pending global approval
SB000 works without causing dangerous changes in the cells
Click on resource name for more details.
18-Nov-2025
New monthly series sponsored by AlbionVC and hosted by UCL Engineering (London, UK)
Podcast from Beyond Biotech-Leveraging the body's protein degradation system to treat disease
Podcast from Beyond Biotech- Targeting inflammation: Transforming disease treatment
Podcast from Beyond Biotech-InflaRx Tackles Inflammation via First-of-its-Kind C5a/C5aR Pathway Strategy
25-Aug-2025
Event about latest progress in the molecular, cellular and organismal basis of aging organised by Uni of Copenhagen (Copenhagen, Denmark)
No blog posts found!